Design and engineering of artificial biosynthetic pathways-where do we stand and where do we go?

被引:3
作者
Sokolova, Nika [1 ]
Peng, Bo [1 ]
Haslinger, Kristina [1 ]
机构
[1] Univ Groningen, Dept Chem & Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands
关键词
biotransformation; engineered microbes; metabolic pathways; sustainability; IN-VITRO; SYNTHETIC BIOLOGY; ESCHERICHIA-COLI;
D O I
10.1002/1873-3468.14745
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The production of commodity and specialty chemicals relies heavily on fossil fuels. The negative impact of this dependency on our environment and climate has spurred a rising demand for more sustainable methods to obtain such chemicals from renewable resources. Herein, biotransformations of these renewable resources facilitated by enzymes or (micro)organisms have gained significant attention, since they can occur under mild conditions and reduce waste. These biotransformations typically leverage natural metabolic processes, which limits the scope and production capacity of such processes. In this mini-review, we provide an overview of advancements made in the past 5 years to expand the repertoire of biotransformations in engineered microorganisms. This ranges from redesign of existing pathways driven by retrobiosynthesis and computational design to directed evolution of enzymes and de novo pathway design to unlock novel routes for the synthesis of desired chemicals. We highlight notable examples of pathway designs for the production of commodity and specialty chemicals, showcasing the potential of these approaches. Lastly, we provide an outlook on future pathway design approaches. Microbial production of commodity and specialty chemicals has the potential to decrease our reliance on fossil fuels and reduce the accompanying environmental effects. The scope of traditional biomanufacturing can be greatly enhanced by constructing new-to-nature pathways toward target chemicals. Here, we outline the principles of artificial pathway design and engineering, highlight notable examples and provide an outlook on its future.image
引用
收藏
页码:2897 / 2907
页数:11
相关论文
共 50 条
  • [21] Heat Shock Proteins in Glioblastoma Biology: Where Do We Stand?
    Iglesia, Rebeca Piatniczka
    de Lima Fernandes, Camila Felix
    Coelho, Barbara Paranhos
    Prado, Mariana Brandao
    Melo Escobar, Maria Isabel
    Dona Rodrigues Almeida, Gustavo Henrique
    Lopes, Marilene Hohmuth
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)
  • [22] Going beyond supplier diversity to economic Inclusion:Where are we now and where do we go from here?
    Sordi, Andrea
    Tate, Wendy L.
    Huang, Feigao
    [J]. JOURNAL OF PURCHASING AND SUPPLY MANAGEMENT, 2022, 28 (02)
  • [23] Cell-free amplification of prions: Where do we stand?
    Cazzaniga, Federico Angelo
    De Luca, Chiara Maria Giulia
    Bistaffa, Edoardo
    Consonni, Alessandra
    Legname, Giuseppe
    Giaccone, Giorgio
    Moda, Fabio
    [J]. PRIONS AND NEURODEGENERATIVE DISEASES, 2020, 175 : 325 - 358
  • [24] Ten years of sustainability: where do we go from here
    Batterham, RJ
    [J]. CHEMICAL ENGINEERING SCIENCE, 2003, 58 (11) : 2167 - 2179
  • [25] The role of nanochitin in biologically-active matrices for tissue engineering-where do we stand?
    Olza, Sheila
    Salaberria, Asier M. M.
    Alonso-Varona, Ana
    Samanta, Ayan
    Fernandes, Susana C. M.
    [J]. JOURNAL OF MATERIALS CHEMISTRY B, 2023, 11 (25) : 5630 - 5649
  • [26] Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
    Tricot, Tine
    De Boeck, Jolan
    Verfaillie, Catherine
    [J]. CELLS, 2020, 9 (03)
  • [27] Where do we stand on the 17 Sustainable Development Goals? An overview on progress
    Halkos, George
    Gkampoura, Eleni-Christina
    [J]. ECONOMIC ANALYSIS AND POLICY, 2021, 70 : 94 - 122
  • [28] Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro, Alexandre
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 154 - 164
  • [29] Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
    Goncalves, Elaine D.
    Dutra, Rafael C.
    [J]. DRUG DISCOVERY TODAY, 2019, 24 (09) : 1845 - 1853
  • [30] Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
    Ebert, Antje D.
    Diecke, Sebastian
    Chen, Ian Y.
    Wu, Joseph C.
    [J]. EMBO MOLECULAR MEDICINE, 2015, 7 (09) : 1090 - 1103